ADMA Biologics (ADMA)
In a report released today, Reni Benjamin from Raymond James maintained a Buy rating on ADMA Biologics, with a price target of $10. The company’s shares closed yesterday at $5.56.
According to TipRanks.com, Benjamin is a 1-star analyst with an average return of -0.1% and a 36.6% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Alpine Immune Sciences Inc, Asterias Biotherapeutics, and Adaptimmune Therapeutics.
Currently, the analyst consensus on ADMA Biologics is a Strong Buy with an average price target of $11.67, which is an 110.1% upside from current levels. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $12 price target.
Bristol Myers (BMY)
Barclays analyst Geoff Meacham maintained a Hold rating on Bristol Myers today and set a price target of $58. The company’s shares closed yesterday at $57.50.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of 4.8% and a 53.5% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Alexion Pharmaceuticals, and United Therapeutics.
Bristol Myers has an analyst consensus of Moderate Buy, with a price target consensus of $61.50, implying a 7.0% upside from current levels. In a report issued on October 8, Guggenheim also initiated coverage with a Hold rating on the stock with a $70 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.